Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-α2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma

Journal of Urology

Volumn 164, Issue 1, 2000, Pages 47-52

  Kaasinen, Eero ^a   Rintala, Erkki ^a   Pere, Anna Kaisa ^a   Kallio, Jukka ^a   Puolakka, Veli Matti ^a   Liukkonen, Tapani ^a   Tuhkanen, Kari ^a   Alfthan, O ^a   Forsell, T ^a   Granbacka, P ^a   Hansson, E ^a   Hellstrom P ^a   Jauhiainen, K ^a   Juusela, H ^a   Kallio, J ^a   Kaasinen, E ^a   Korhonen, H ^a   Lahdes Vasama, T ^a   Liukkonen, T ^a   Lukkarinen, O ^a   Nurmi, M ^a   Pere, A K ^a   Puolakka, V M ^a   Rajala, P ^a   Rautanen, M ^a   Rintala, E ^a   Talja, M ^a   Tuhkanen, K ^a   Viitanen, J ^a   more..

^a NONE

Author keywords

Bladder; Interferons; Mitomycin; Mycobacterium bovis; Papillary carcinoma

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CLINICAL TRIAL; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT CANCER; TREATMENT OUTCOME;

EID: 0033935330     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67446-0     Document Type: Article

References (20)

1. Belldegrun, A. S., Franklin, J. R., O'Donnell, M. A. et al: Superficial bladder cancer: the role of interferon-α. J Urol, 159: 1793, 1998
2. Vegt, P. D., Witjes, J. A., Witjes, W. P. J. et al: A randomized study of intravesical Mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol, 153: 929, 1995
3. Witjes, J. A., van der Meijden, A. P., Sylvester, R. et al: Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. Urology, 52: 403, 1998
4. Lamm, D. L.: BCG in perspective: advances in the treatment of superficial bladder cancer. Eur Urol, suppl., 27: 2, 1995
5. Cookson, M. S., Herr, H. W., Zhang, Z. F. et al: The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol, 158: 62, 1997
6. Herr, H. W.: Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol, 80: 762, 1997
7. Rintala, E., Jauhiainen, K., Kaasinen, E. et al: Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. J Urol, 156: 56, 1996
8. Rintala, E., Jauhiainen, K., Rajala, P. et al: Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. J Urol, 154: 2050, 1995
9. Freedman, L. S.: Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1: 121, 1982
10. Malmström, P.-U., Wijkström, H., Lundholm, C. et al: 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol, 161: 1124, 1999
11. Lamm, D. L., Blumenstein, B. A., Crawford. E. D. et al: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Eng J Med, 325: 1205, 1991
12. Witjes, J. A., Caris, C. T. M., Mungan, N. A. et al: Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitoraycin C alone in patients with superficial bladder cancer. J Urol, 160: 1668, 1998
13. Rintala, E, Jauhiainen, K., Alfthan, O. et al: Intravesical chemotherapy (MMC) versus immunotherapy (BCG) in superficial bladder cancer. Eur Urol, 20: 19, 1991
14. Lamm, D. L., Blumenstein, B., Sarosdy, M. et al: Significant long-term patient benefit with BCG maintenance therapy: a Southwest Oncology Group Study. J Urol, suppl., 157: 213, abstract 831, 1997
15. Lamm, D. L.: Towards the optimal BCG regimen: comparison of maintenance schedules. In: Optimal Therapy for Patients With High-Risk Superficial Bladder Cancer: Controversy and Consensus. MEDICINE Publishing Foundation Symposium Series 37. Edited by A. Böhle and D. Jocham, Oxford: Medicine Group (Education), p. 103, 1997
16. Kurth, K. H., Denis, L., Bouffioux, C. et al: Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer, 31A: 1840, 1995
17. Kurth, K. H.: Clinical characterization of risk profiles. In: Optimal Therapy for Patients With High-Risk Superficial Bladder Cancer: Controversy and Consensus. MEDICINE Publishing Foundation Symposium Series 37. Edited by A. Böhle and D. Jocham. Oxford: Medicine Group (Education), p. 25, 1997
18. Torti, F. M., Shortliffe, L. D., Williams, R. D. et al: Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J Clin Oncol, 6: 476, 1988
19. Gan, Y.-H., Zhang, Y., Khoo, H. E. et al: Antitumour immunity of Bacillus Calmette-Guerin and Interferon alpha in murine bladder cancer. Eur J Cancer, 35: 1123, 1999
20. Raitanen, M.-P. and Lukkarinen, O.: A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Br J Urol, 76: 697, 1995